Fully automated dual-color dual-hapten silver in situ hybridization staining for MYC amplification: A diagnostic tool for discriminating secondary angiosarcoma

Journal of Cutaneous Pathology

Volumn 41, Issue 3, 2014, Pages 286-292

  Ko, Jennifer S ^a,c   Billings, Steven D ^a   Lanigan, Christopher P ^a   Buehler, Darya ^b   Fernandez, Anthony P ^a   Tubbs, Raymond R ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

^c Pathology and Laboratory Medicine Institute   (United States)

Author keywords

atypical vascular lesions; in situ hybridization; MYC; secondary angiosarcoma; soft tissue tumors

Indexed keywords

MYC PROTEIN; MYC PROTEIN, HUMAN; SILVER;

ADULT; AGED; ANGIOSARCOMA; ARTICLE; ATYPICAL VASCULAR LESIONS; CHEMISTRY; FEMALE; GENE AMPLIFICATION; GENETICS; HUMAN; IN SITU HYBRIDIZATION; MALE; METABOLISM; METHODOLOGY; MIDDLE AGED; MYC; PATHOLOGY; RADIATION INDUCED NEOPLASM; RETROSPECTIVE STUDY; SECONDARY ANGIOSARCOMA; SKIN TUMOR; SOFT TISSUE TUMORS; VERY ELDERLY;

ATYPICAL VASCULAR LESIONS; IN SITU HYBRIDIZATION; MYC; SECONDARY ANGIOSARCOMA; SOFT TISSUE TUMORS;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; GENE AMPLIFICATION; HEMANGIOSARCOMA; HUMANS; IN SITU HYBRIDIZATION; MALE; MIDDLE AGED; NEOPLASMS, RADIATION-INDUCED; PROTO-ONCOGENE PROTEINS C-MYC; RETROSPECTIVE STUDIES; SILVER; SKIN NEOPLASMS;

EID: 84894589684     PISSN: 03036987     EISSN: 16000560     Source Type: Journal    
DOI: 10.1111/cup.12278     Document Type: Article

References (25)

1. Billings SD, McKenney JK, Folpe AL, Hardacre MC, Weiss SW,. Cutaneous angiosarcoma following breast-conserving surgery and radiation: an analysis of 27 cases. Am J Surg Pathol 2004; 28: 781.
2. Perez MC, Padhya TA, Messina JL, et al. Cutaneous angiosarcoma: a single-institution experience. Ann Surg Oncol 2013; 20: 3391.
3. Patton KT, Deyrup AT, Weiss SW,. Atypical vascular lesions after surgery and radiation of the breast: a clinicopathologic study of 32 cases analyzing histologic heterogeneity and association with angiosarcoma. Am J Surg Pathol 2008; 32: 943.
4. Weaver J, Billings SD,. Postradiation cutaneous vascular tumors of the breast: a review. Semin Diagn Pathol 2009; 26: 141.
5. Mentzel T, Schildhaus HU, Palmedo G, Büttner R, Kutzner H,. Postradiation cutaneous angiosarcoma after treatment of breast carcinoma is characterized by MYC amplification in contrast to atypical vascular lesions after radiotherapy and control cases: clinicopathological, immunohistochemical and molecular analysis of 66 cases. Mod Pathol 2012; 25: 75.
6. Guo T, Zhang L, Chang NE, et al. Consistent MYC and FLT4 gene amplification in radiation-induced angiosarcomas but not in other radiation-associated atypical vascular lesions. Genes Chromosomes Cancer 2011; 50: 25.
7. Fernandez AP, Sun Y, Tubbs RR, Goldblum JR, Billings SD,. FISH for MYC amplification and anti-MYC immunohistochemistry: useful diagnostic tools in the assessment of secondary angiosarcoma and atypical vascular proliferations. J Cutan Pathol 2012; 39: 234.
8. Powell RD, Pettay JD, Powell WC, et al. Metallographic in situ hybridization. Hum Pathol 2007; 38: 1145.
9. Gruver AM, Peerwani Z, Tubbs RR,. Out of the darkness and into the light: bright field in situ hybridisation for delineation of ERBB2 (HER2) status in breast carcinoma. J Clin Pathol 2010; 63: 210.
10. Bartlett JM, Starczynski J, Atkey N, et al. HER2 testing in the UK: recommendations for breast and gastric in-situ hybridisation methods. J Clin Pathol 2011; 64: 649.
11. Koh YW, Lee HJ, Lee JW, Kang J, Gong G,. Dual-color silver-enhanced in situ hybridization for assessing HER2 gene amplification in breast cancer. Mod Pathol 2011; 24: 794.
12. Tutorial video at: http://www.youtube.com/watch?v= UoE3CftY0Fg&feature=share&list=PL2EC3A34F9F5CA19B
13. Lindet C, Neuville A, Penel N, et al. Localised angiosarcomas: the identification of prognostic factors and analysis of treatment impact. A retrospective analysis from the French Sarcoma Group (GSF/GETO). Eur J Cancer 2013; 49: 369.
14. Fineberg S, Rosen PP,. Cutaneous angiosarcoma and atypical vascular lesions of the skin and breast after radiation therapy for breast carcinoma. Am J Clin Pathol 1994; 102: 757.
15. Young RJ, Brown NJ, Reed MW, Hughes D, Woll PJ,. Angiosarcoma. Lancet Oncol 2010; 11: 983.
16. Brenn T, Fletcher CD,. Radiation-associated cutaneous atypical vascular lesions and angiosarcoma: clinicopathologic analysis of 42 cases. Am J Surg Pathol 2005; 29: 983.
17. Thariat J, Italiano A, Collin F, et al. Not all sarcomas developed in irradiated tissue are necessarily radiation-induced-spectrum of disease and treatment characteristics. Crit Rev Oncol Hematol 2012; 83: 393.
18. Patton KT, Deyrup AT, Weiss SW,. Atypical vascular lesions after surgery and radiation of the breast: a clinicopathologic study of 32 cases analyzing histologic heterogeneity and association with angiosarcoma. Am J Surg Pathol 2008; 32: 943.
19. Brenn T, Fletcher CD,. Postradiation vascular proliferations: an increasing problem. Histopathology 2006; 48: 106.
20. Mattoch IW, Robbins JB, Kempson RL, Kohler S,. Post-radiotherapy vascular proliferations in mammary skin: a clinicopathologic study of 11 cases. J Am Acad Dermatol 2007; 57: 126.
21. Manner J, Radlwimmer B, Hohenberger P, et al. MYC high level gene amplification is a distinctive feature of angiosarcomas after irradiation or chronic lymphedema. Am J Pathol 2010; 176: 34.
22. Italiano A, Thomas R, Breen M, et al. The miR-17-92 cluster and its target THBS1 are differentially expressed in angiosarcomas dependent on MYC amplification. Genes Chromosomes Cancer 2012 Jun; 51: 569.
23. Feller JK, Mahalingam M,. c-MYC and cutaneous vascular neoplasms. Am J Dermatopathol 2013; 35: 364.
24. Feller K, Yang S, Tung N, Lee J, Mahalingam M,. c-MYC in Kaposi's sarcoma: analyses by fluorescent in situ hybridization and immunohistochemistry. J Eur Acad Dermatol Venereol 2014; 28: 120.
25. Nitta H, Hauss-Wegrzyniak B, Lehrkamp M, et al. Development of automated brightfield double in situ hybridization (BDISH) application for HER2 gene and chromosome 17 centromere (CEN 17) for breast carcinomas and an assay performance comparison to manual dual color HER2 fluorescence in situ hybridization (FISH). Diagn Pathol 2008; 3: 41.